Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients

Lucia Del Mastro, Matteo Lambertini, Claudia Bighin, Alessia Levaggi, Alessia D'Alonzo, Sara Giraudi, Paolo Pronzato

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Trastuzumab is a humanized monoclonal antibody against the extracellular domain of hEGF receptor-2 (HER2). Trastuzumab in combination with chemotherapy has proven efficacy in treating both early and metastatic HER2-positive breast cancer. In the metastatic setting, the addition of trastuzumab to chemotherapy is associated with a statistically significant longer time to disease progression, higher rate of objective response and improvement in overall survival. Trastuzumab efficacy is not influenced by hormone receptor status, but differences in median overall survival exist between HER2-positive and HER2-negative states. Reassessment of the benefit of re-exposing patients with metastatic breast cancer to trastuzumab following relapse in the adjuvant setting is necessary. Ongoing research into new HER2-targeted therapies and trials involving combination anti-HER2 drug therapy without chemotherapy show promise. This review is focused on the available results obtained with the use of trastuzumab in the subset of HER2-positive breast cancer patients with metastatic disease.

Original languageEnglish
Pages (from-to)1391-1405
Number of pages15
JournalExpert Review of Anticancer Therapy
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Antibodies, Monoclonal, Humanized
Survival
Combination Drug Therapy
Disease Progression
Trastuzumab
Hormones
Recurrence
Research

Keywords

  • chemotherapy
  • HER2
  • metastatic breast cancer
  • trastuzumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. / Mastro, Lucia Del; Lambertini, Matteo; Bighin, Claudia; Levaggi, Alessia; D'Alonzo, Alessia; Giraudi, Sara; Pronzato, Paolo.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 11, 11.2012, p. 1391-1405.

Research output: Contribution to journalArticle

Mastro, Lucia Del ; Lambertini, Matteo ; Bighin, Claudia ; Levaggi, Alessia ; D'Alonzo, Alessia ; Giraudi, Sara ; Pronzato, Paolo. / Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. In: Expert Review of Anticancer Therapy. 2012 ; Vol. 12, No. 11. pp. 1391-1405.
@article{9254f6f0c3524fa29fe27ead81114a24,
title = "Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients",
abstract = "Trastuzumab is a humanized monoclonal antibody against the extracellular domain of hEGF receptor-2 (HER2). Trastuzumab in combination with chemotherapy has proven efficacy in treating both early and metastatic HER2-positive breast cancer. In the metastatic setting, the addition of trastuzumab to chemotherapy is associated with a statistically significant longer time to disease progression, higher rate of objective response and improvement in overall survival. Trastuzumab efficacy is not influenced by hormone receptor status, but differences in median overall survival exist between HER2-positive and HER2-negative states. Reassessment of the benefit of re-exposing patients with metastatic breast cancer to trastuzumab following relapse in the adjuvant setting is necessary. Ongoing research into new HER2-targeted therapies and trials involving combination anti-HER2 drug therapy without chemotherapy show promise. This review is focused on the available results obtained with the use of trastuzumab in the subset of HER2-positive breast cancer patients with metastatic disease.",
keywords = "chemotherapy, HER2, metastatic breast cancer, trastuzumab",
author = "Mastro, {Lucia Del} and Matteo Lambertini and Claudia Bighin and Alessia Levaggi and Alessia D'Alonzo and Sara Giraudi and Paolo Pronzato",
year = "2012",
month = "11",
doi = "10.1586/era.12.107",
language = "English",
volume = "12",
pages = "1391--1405",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients

AU - Mastro, Lucia Del

AU - Lambertini, Matteo

AU - Bighin, Claudia

AU - Levaggi, Alessia

AU - D'Alonzo, Alessia

AU - Giraudi, Sara

AU - Pronzato, Paolo

PY - 2012/11

Y1 - 2012/11

N2 - Trastuzumab is a humanized monoclonal antibody against the extracellular domain of hEGF receptor-2 (HER2). Trastuzumab in combination with chemotherapy has proven efficacy in treating both early and metastatic HER2-positive breast cancer. In the metastatic setting, the addition of trastuzumab to chemotherapy is associated with a statistically significant longer time to disease progression, higher rate of objective response and improvement in overall survival. Trastuzumab efficacy is not influenced by hormone receptor status, but differences in median overall survival exist between HER2-positive and HER2-negative states. Reassessment of the benefit of re-exposing patients with metastatic breast cancer to trastuzumab following relapse in the adjuvant setting is necessary. Ongoing research into new HER2-targeted therapies and trials involving combination anti-HER2 drug therapy without chemotherapy show promise. This review is focused on the available results obtained with the use of trastuzumab in the subset of HER2-positive breast cancer patients with metastatic disease.

AB - Trastuzumab is a humanized monoclonal antibody against the extracellular domain of hEGF receptor-2 (HER2). Trastuzumab in combination with chemotherapy has proven efficacy in treating both early and metastatic HER2-positive breast cancer. In the metastatic setting, the addition of trastuzumab to chemotherapy is associated with a statistically significant longer time to disease progression, higher rate of objective response and improvement in overall survival. Trastuzumab efficacy is not influenced by hormone receptor status, but differences in median overall survival exist between HER2-positive and HER2-negative states. Reassessment of the benefit of re-exposing patients with metastatic breast cancer to trastuzumab following relapse in the adjuvant setting is necessary. Ongoing research into new HER2-targeted therapies and trials involving combination anti-HER2 drug therapy without chemotherapy show promise. This review is focused on the available results obtained with the use of trastuzumab in the subset of HER2-positive breast cancer patients with metastatic disease.

KW - chemotherapy

KW - HER2

KW - metastatic breast cancer

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84871264662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871264662&partnerID=8YFLogxK

U2 - 10.1586/era.12.107

DO - 10.1586/era.12.107

M3 - Article

VL - 12

SP - 1391

EP - 1405

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 11

ER -